Abstract A higher inoculum size of b-lactamase-positive Haemophilus influenzae is reported to increase minimum inhibitory concentrations (MICs) for b-lactams. However, the effect of inoculum size of b-lactamase-negative, ampicillin-resistant H. influenzae (BLNAR) on MICs for carbapenems has not been investigated. This study evaluated the effect of inoculum size on MICs for carbapenems and other b-lactams in nine clinical isolates of BLNAR. The MICs were determined by both the standard method described by the Clinical and Laboratory Standards Institute (final inoculum size of 5 9 10 5 colony-forming units [CFU]/ml) and a modified method (final inoculum size of 5 9 10 6 CFU/ml) using viable cell counts. The findings showed that the higher inoculum size increased MICs for imipenem, meropenem, panipenem, biapenem, ampicillin, ceftazidime, and ceftriaxone. The inoculum effect (4 log 2 dilution or a greater increase in the MIC) with imipenem, meropenem, panipenem, and biapenem was found in three, five, two, and two isolates, respectively. The magnitude of the inoculum effect for panipenem significantly increased with the levels of MICs, but correlation between them for the others was not statistically significant. The mutations of penicillin-binding protein genes had little relevance to the reduced susceptibility to carbapenems or to the magnitude of the inoculum effect. These results suggest that MIC determination using turbidity can produce interpretive errors in the antimicrobial susceptibility testing of BLNAR for carbapenems because of their inoculum effect. Thus, accurate adjustment of inoculum size, such as viable cell count, is helpful for confirming the true MICs when the isolates are interpreted as ''resistant'' by turbidity-based MIC determination.
Introduction
Haemophilus influenzae is an important pathogen that causes otitis media, respiratory tract infections, and purulent meningitis. The emergence of ampicillin-resistant H. influenzae isolates is a clinical problem. The major mechanisms responsible for b-lactam resistance in H. influenzae include the production of b-lactamases such as the TEM and ROB types [14, 23] , the decreased affinity of b-lactams for the penicillin-binding proteins (PBPs) [13, 15] , and the efflux systems (AcrAB) [12, 19] .
Recent studies have demonstrated particularly that alterations in the PBPs contribute considerably to b-lactam resistance in b-lactamase-negative, ampicillin-resistant H. influenzae (BLNAR), which is defined as a strain showing an ampicillin minimum inhibitory concentration (MIC) of 2 lg/ml or greater [4, 15] . In BLNAR, amino acid mutations in PBP3 are involved in b-lactam resistance [10, 22] . Accordingly, to treat H. influenzae infections, it is important to determine the varying degrees of b-lactam resistance.
The pharmacokinetics/pharmacodynamics theory for antimicrobial use is widely applied to daily clinical practice, and hence the accurate determination of MIC is of critical importance to evaluation of the time above MIC and the area under the time-concentration curve/MIC. However, the value of MIC is known to be affected by several factors, resulting in fluctuation. In particular, quality assessment studies have shown discrepancies in the susceptibilities of H. influenzae between laboratories [3] . In microdilution testing, different conditions such as media, supplements, and inoculum size markedly influenced the susceptibility of H. influenzae [4] .
The inoculum effect is a laboratory phenomenon observed as a significant increase in the MIC of antimicrobials when the number of organisms inoculated is increased [1] . This effect also is reported for H. influenzae. For example, Gould et al. [11] demonstrated the inoculum effect in both b-lactamase-negative isolates and b-lactamase-positive isolates when MIC is determined by turbidity. Similarly, Balko et al. [2] also showed the inoculum effect of both b-lactamase-negative and b-lactamase-positive isolates in the assessment of MIC by turbidity but not by viable cell count. They concluded that the true inoculum effect, determined by viable cell count, not by turbidity, was present only in b-lactamase-positive strains. However, the inoculum effect generally occurred in H. influenzae regardless of b-lactamase when MIC was assessed by turbidity.
In the practical setting for MIC determination of H. influenzae, bacterial burden usually is assessed by turbidity. Clinically, it therefore would be important to evaluate the inoculum effect by turbidity determination of susceptibility of various bacteria to a range of antibacterial drugs.
Recently, several studies demonstrated that the MICs of cephalosporins for H. influenzae, including BLNAR, were gradually increased, although third-generation cephalosporins still possessed the activity against BLNAR isolates [5, 18] . The antimicrobial activity of cephalosporins against H. influenzae is due to their affinity for PBP3. Thus, under the selective pressure imposed by cephalosporin usage, strains with mutations in the ftsI gene, which reduce the binding affinity on PBP3, are selected. The increased use of cephalosporins, particularly with oral administration, may lead to the selection of highly BLNAR strains [17] , and possibly some of them may acquire resistance to certain third-generation cephalosporins, such as ceftazidime [18] .
On the other hand, carbapenems were considered a useful alternative to expanded-spectrum cephalosporins for the treatment of invasive infections caused by BLNAR such as pneumonia and meningitis because of their highlevel activity against H. influenzae [6, 16] . In particular, meropenem may be a useful alternative to cefotaximeresistant H. influenzae infection [16] . However, no study has examined the inoculum effect of H. influenzae on the susceptibility of carbapenems.
The current study was conducted to clarify the effect of inoculum sizes on the MICs for carbapenem in clinical isolates of BLNAR, and also to compare this effect with other b-lactams, such as ampicillin and cephalosporins.
Materials and Methods

Bacterial Strains
The isolated strains of H. influenzae were collected as causative pathogens at city hospitals in the Shizuoka and Aichi Prefecture from 2001 to 2005. Among numerous strains found in available clinical laboratories, we selected BLNAR-type strains that also demonstrated a reduced susceptibility to carbapenems. As a result, nine clinical isolates (strains 1-9) were chosen as candidates for further investigation.
Identification was performed by standard biochemical tests in our clinical microbiology laboratory. The pulsedfield gel electrophoresis patterns of the SmaI-restricted fragments of the chromosomal DNA from the nine isolates varied. Bacteria were stored at -70°C in heart infusion broth (Nissui Pharumaceutical, Tokyo, Japan) supplemented with Strepto-Haemo Supplement ''Eiken'' (Eiken Chemical, Tokyo, Japan) containing 20% glycerol. Subsequently, the bacteria were inoculated on chocolate agar plates (Eiken Chemical) and incubated at 35°C for 18-24 h in an atmosphere of 7% carbon dioxide (CO 2 ). Haemophilus influenzae ATCC49766 (ampicillin susceptible, abbreviated as Ref-BLNAS) and ATCC49247 (BLNAR, abbreviated as Ref-BLNAR) were used as reference strains.
Antimicrobial Agents
The antimicrobials used were eight antibiotics including ampicillin, biapenem (Meiji Seika Kaisha, Tokyo, Japan), ceftadizime (GlaxoSmithKline, Tokyo, Japan), ceftriaxone (Roche, Tokyo, Japan), imipenem (Banyu Pharmaceutical, Tokyo, Japan), panipenem (Sankyo, Tokyo, Japan), meropenem (Dainippon Sumitomo Pharmaceutical, Osaka, Japan), and levofloxacin (Daiichi Pharmaceutical, Tokyo, Japan).
Susceptibility Testing
The MICs were determined using the broth dilution method described by the Clinical and Laboratory Standards Institute (CLSI) as a standard method [8] . The bacterial cells were suspended in Haemophilus Test Medium (HTM) broth (Dade Behring, Tokyo, Japan). After the bacterial suspension had been serially diluted 10-fold, inoculum size was determined by visually viable cell counts. For the MIC determination, bacterial cells were inoculated to produce a final inoculum size of 5 9 10 5 colony-forming units (CFU)/ml (final antimicrobial concentrations ranging from 0.01 to 64 lg/ml). The MIC interpretative criteria for ampicillin, ceftadizime, ceftriaxone, imipenem, and meropenem followed those of the CLSI [9] . The MIC breakpoints of the other antimicrobials were not defined.
For the modified broth dilution susceptibility testings, bacterial cells were inoculated to produce a final inoculum size of 5 9 10 6 CFU/ml. After the bacterial suspension was serially diluted 10-fold, inoculum size was determined by visually viable cell counts. Viable cell counts were performed three times to confirm the desired final inoculum size (5 9 10 6 CFU/ml). All culture conditions except inoculum size were performed in accordance with the standard method, defined as the modified method. The discrepancies of the MICs were defined as ''not determined'' if the MICs were 0.01 lg/ml or less by the standard method. Whether an inoculum effect was positive or not was determined as a fourfold or greater increase in the MIC.
Amplification and DNA Sequencing
We determined the amino acid sequences in PBP3 from nine clinical isolates and two reference strains (Ref-BLNAS and Ref-BLNAR) of H. influenzae. The chromosomal DNA of H. influenzae was extracted with a DNeasy tissue kit (Qiagen, Tokyo, Japan) in accordance with the manufacturer's instructions. The PCR amplification for H. influenzae DNA was performed as follows: 1 min of denaturing at 94°C and 30 cycles of denaturing at 94°C for 30 s, then annealing at 60°C for 2 min and extension at 74°C for 30 s.
The amplification was performed with KOD dash enzyme (Toyobo, Osaka, Japan) according to the manufacturer's recommendations. The PCR products were sequenced using the BigDye terminator v 3.1 Taq cycle sequencing ready reaction kit with AmpliTaq DNA polymerase (Perkin-Elmer, Foster City, CA, USA) and an automated DNA sequencing system (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems, Foster City, CA, USA). The DNA and amino acid sequences in the BLNAR and Ref-BLNAR were compared with those in Ref-BLNAS.
Statistical Analysis
The correlation between the magnitudes of the inoculum effect and the levels of MICs was evaluated using the Pearson correlation test (r value). These analyses were performed using the statistical program SPSS version 15.0 J for Windows (SPSS Japan Inc., Tokyo, Japan). All P values less than 0.05 were considered statistically significant.
Results
Antimicrobial Susceptibilities
The results of the susceptibility testing for eight antimicrobials are summarized in Table 1 . As seen in Table 1 , all nine isolates showed the BLNAR phenotype (MICs of ampicillin C2 lg/ml and b-lactamase negative). Among four carbapenems, meropenem showed the lowest MICs for all BLNAR isolates. Two of nine isolates, strains 8 and 9, showed higher MICs for imipenem ([4 lg/ml), meropenem ([0.5 lg/ml), or both. Two isolates (strains 8 and 9) and one isolate (strain 4) had reduced susceptibilities to carbapenems and ceftazidime, respectively. Strains 8 and 9 were susceptible to cephalosporins and levofloxacin, whereas strain 4 was susceptible to carbapenems.
Effect of Inoculum Size on the MICs Table 2 shows the results of susceptibility testing with higher inoculum size (5 9 10 6 CFU/ml) and summarizes the comparison of the MIC results by the modified method with those by the standard method. The difference between the two methods was inoculum size. A zero indicates that the MICs between the two methods are identical. Likewise, the number indicated means the difference in the number of log 2 dilution.
As shown in Table 2 , the increase in inoculum size frequently gave rise to a significant elevation of MIC values. The MICs for levofloxacin were 0.01 lg/ml or less by the standard method in all isolates, whereas they were 0.01 lg/ml or less in five isolates, 0.03 lg/ml in three isolates, and 0.06 lg/ml in one isolate by the modified method. The discrepancies in the MICs for ceftriaxone were not determined for H. influenzae Ref-BLNAS or strain 3 because the MICs were 0.01 lg/ml or less by both the standard and modified methods.
A positive inoculum effect determined at a fourfold or greater increase in MIC was observed in three of nine isolates (33%) for imipenem, in five of nine isolates (55%) for meropenem, in two of nine isolates (22%) for panipenem, in two of nine isolates (22%) for biapenem, in five of nine isolates (55%) for ampicillin, in four of nine isolates (44%) for ceftadizime, and in five of eight isolates (62%) for ceftriaxone. Strains 6 and 9 were notable for positive inoculum effects on seven antimicrobials, except for biapenem. The magnitude of the inoculum effect for panipenem significantly increased with the levels of MICs (r = 0.710; P \ 0.05), but correlation between the two for imipenem (r = 0.414; P = 0.268), meropenem (r = 0.030; P = 0.938), and biapenem (r = -0.366; P = 0.332) was not significant. On the other hand, the magnitudes of the inoculum effect for cephalosporins were widely varied with the levels of MICs. There was no relationship between the inoculum effect and susceptibilities to ampicillin.
Genetic Analysis of the PBP3 Gene
The deduced amino acid sequences encoding the transpeptidase region of PBP3 were aligned in comparison with the corresponding sequence of H. influenzae Ref-BLNAS (Table 3 ). All nine isolates and Ref-BLNAR had the Asn-526-to-Lys mutation in PBP3.
Of the nine isolates, strains 2, 5, 6, 7, and 8 demonstrated additional mutations such as Met-377 to Ile, Ser-385 to Thr, Leu-389 to Phe, and Val-562 to Leu simultaneously, with the lack of the Met-377 mutation in strain 5.
In strains 8 and 9, showing higher MICs for imipenem, meropenem, or both, strain 8 showed a wide range of mutations, whereas strain 9 had fewer mutations of PBP3. Although the Asn-526-to-Lys substitution seems to play a role in resistance to imipenem [7] , all clinical isolates of BLNAR and Ref-BLNAR had the mutation of Asn-526 to Lys in our study. Strain 9, showing higher MICs for imipenem and meropenem, had mutations of Asp-350 to Asn, Table 2 Antimicrobial susceptibilities (inoculum size of 5 9 10 6 CFU/ml) and discrepancies of the minimum inhibitory concentrations (MICs) for b-lactams (4) 1 (1) 8 (2) 32 (4) 64 (10) Ser-357 to Asn, Ala-502 to Thr, and Asn-526 to Lys in combination, but there was no relation between PBP3 mutations and reduced susceptibility to carbapenems. For our clinical isolates of BLNAR, no association was found between the inoculum effect and the sites and/or numbers of amino acid mutations of PBP3. We also have performed genetic studies on PBP 1a, 1b, 2, 4, and 5 (data not shown). There were no common mutations in these PBPs. Consequently, the mutations of PBP genes had little relevance to the reduced susceptibility to carbapenems in terms of their mutation sites.
Discussion
This study evaluated the effect of inoculum sizes on the MICs for carbapenems and other b-lactams in clinical isolates of BLNAR including two isolates with reduced susceptibility to imipenem (strains 8 and 9). The results showed that a higher inoculum size (5 9 10 6 CFU/ml) increased the MICs for imipenem, meropenem, panipenem, biapenem, and other b-lactams (ampicillin, ceftazidime, ceftriaxone) in all isolates except one (strain 2). In clinical isolates of BLNAR, susceptibilities determined by turbidity for carbapenems can be affected by the inoculum size, as shown for ampicillin and cephalosporins.
An inoculum effect is a laboratory phenomenon defined as a fourfold or greater increase in the MIC when the MICs are determined using a higher inoculum size [1] . Based on this definition, the current study for the first time showed the inoculum effect of carbapenems in clinical isolates of BLNAR with assessment of MIC by viable cell counts.
The frequencies of our isolates showing the inoculum effect varied among the carbapenems. The MICs for meropenem often were affected by inoculum size, as shown for other b-lactams, resulting in the highest frequency of isolates showing the inoculum effect among the four carbapenems. Regarding the magnitude of the inoculum effect, the effect of inoculum size on the MIC was the most pronounced for meropenem among the carbapenems. Discrepancies in the MICs for meropenem were 7 log 2 dilutions or greater for three isolates (strains 6, 7, and 8).
In this study, only two isolates were finally defined as reduced susceptibilities to carbapenems when the bacterial cells were accurately inoculated to produce a final inoculum size of 5 9 10 5 CFU/ml, although we selected the BLNAR isolates with reduced susceptibility to carbapenems among numerous strains in assessment of MIC by turbidity. This discrepancy might be accounted for by the large aggregates or spherical bodies often seen with large inoculum size. Because the cells of H. influenzae are smaller than those of other gram-negative bacilli, H. influenzae suspensions usually contain a larger number of cells when its turbidity is adjusted to equal that commonly used for Escherichia coli suspensions [21] . Although viable-count MIC is more accurate than turbidity-based MIC, especially when high initial doses of bacteria are inoculated, turbidity-based MIC currently is broadly used in the clinical setting.
Taken together, these data suggest that susceptible strains can be misinterpreted as ''resistant'' because slight differences in inoculum size can increase the MICs from the susceptible category to the resistant category in routine MIC assessment by turbidity. Thus, it is essential to determine the inoculum size accurately in the performance of quantitative antimicrobial susceptibility testing according to CLSI for b-lactams including carbapenems. Previous studies reported that amino acid mutations surrounding the conserved SSN (Ser379-Ser-Asn) and KTG (Lys512-Thr-Gly) motif are relevant to b-lactam resistance [10, 20] . In the current study, all the BLNAR clinical isolates had amino acid mutation of Asn-526 to Lys in the transpeptidase region of PBP3, although no mutation was found near the SSN motif in four BLNAR isolates or Ref-BLNAR.
These results are consistent with the previous reports that ampicillin resistance is conferred by diverse amino acid mutation patterns in the transpeptidase region of PBP3 in BLNAR isolates [12] . However, our clinical isolates of BLNAR showed no association between the inoculum effect and the sites or numbers of amino acid mutations of PBP3. Our results suggest that the inoculum effect on susceptibilities for b-lactams cannot be predicted based on the amino acid mutation patterns of PBP3.
In addition, no specific mutation responsible for the reduced susceptibility to carbapenems was identified in PBP3. These results agree with a previous report that carbapenem resistance in H. influenzae could not be explained solely by the amino acid mutations in PBP3 [17] . The mechanisms for carbapenem resistance of H. influenzae remain to be determined, but mutations other than those of PBPs, such as efflux pumps, might be involved. Further studies with larger numbers of isolates are needed to identify what factors affect carbapenem resistance.
In conclusion, we characterized the effect of inoculum size on MICs for carbapenems in clinical isolates of BLNAR. Our results show that a higher inoculum size increased the MICs for carbapenems in the BLNAR isolates. Determination of MIC using turbidity, which is widely used in clinical practice, can produce interpretive errors (i.e., misinterpretation of a susceptible strain as a resistant strain) in the antimicrobial susceptibility testing of BLNAR for carbapenems because of their inoculum effect. Thus, accurate adjustment of inoculum size, such as a viable cell count, is helpful for confirmation of the true MICs when the isolates are interpreted as ''resistant'' by turbidity-based MIC determination.
